MX2024010292A - Regímenes de dosificación para la mitigación del síndrome de liberación de citocinas - Google Patents

Regímenes de dosificación para la mitigación del síndrome de liberación de citocinas

Info

Publication number
MX2024010292A
MX2024010292A MX2024010292A MX2024010292A MX2024010292A MX 2024010292 A MX2024010292 A MX 2024010292A MX 2024010292 A MX2024010292 A MX 2024010292A MX 2024010292 A MX2024010292 A MX 2024010292A MX 2024010292 A MX2024010292 A MX 2024010292A
Authority
MX
Mexico
Prior art keywords
cytokine release
release syndrome
mitigating
dosing regimens
administration
Prior art date
Application number
MX2024010292A
Other languages
English (en)
Spanish (es)
Inventor
Srikanth R Ambati
Aafia Chaudhry
Hesham Mohamed
Toroghi Masood Khaksar
Min Zhu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024010292A publication Critical patent/MX2024010292A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024010292A 2022-02-25 2024-08-21 Regímenes de dosificación para la mitigación del síndrome de liberación de citocinas MX2024010292A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263313932P 2022-02-25 2022-02-25
US202263393212P 2022-07-28 2022-07-28
US202263420782P 2022-10-31 2022-10-31
US202263424210P 2022-11-10 2022-11-10
US202363440304P 2023-01-20 2023-01-20
PCT/US2023/013836 WO2023164143A1 (en) 2022-02-25 2023-02-24 Dosing regimens for mitigation of cytokine release syndrome with odronextamab

Publications (1)

Publication Number Publication Date
MX2024010292A true MX2024010292A (es) 2024-12-06

Family

ID=85778997

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010292A MX2024010292A (es) 2022-02-25 2024-08-21 Regímenes de dosificación para la mitigación del síndrome de liberación de citocinas

Country Status (11)

Country Link
US (1) US20230272118A1 (https=)
EP (1) EP4482524A1 (https=)
JP (1) JP2025508832A (https=)
KR (1) KR20240167457A (https=)
CN (1) CN119156226A (https=)
AU (1) AU2023224098A1 (https=)
CA (1) CA3244791A1 (https=)
IL (1) IL315011A (https=)
MX (1) MX2024010292A (https=)
TW (1) TW202400228A (https=)
WO (1) WO2023164143A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CA3110513A1 (en) * 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
TW202135860A (zh) 2019-12-10 2021-10-01 美商再生元醫藥公司 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物

Also Published As

Publication number Publication date
AU2023224098A1 (en) 2024-09-12
IL315011A (en) 2024-10-01
US20230272118A1 (en) 2023-08-31
WO2023164143A1 (en) 2023-08-31
CN119156226A (zh) 2024-12-17
JP2025508832A (ja) 2025-04-10
TW202400228A (zh) 2024-01-01
EP4482524A1 (en) 2025-01-01
KR20240167457A (ko) 2024-11-26
CA3244791A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
MX2021002190A (es) Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20.
CY1123211T1 (el) Meθοδoi γia th θepaπeytikh antimetωπισh ή thn προληψη thς hmikpaniaς
WO2019147805A3 (en) Regulatory t cells targeted with chimeric antigen receptors
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
EA201891495A1 (ru) Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза
JOP20200177A1 (ar) طرق علاج السرطان باستخدام الأجسام المضادة anti-pd-1 المناهضة
MX2018016364A (es) Anticuerpos anti-pd-l1.
MX2019005438A (es) Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3.
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2021009041A (es) Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX384989B (es) Uso de un agonista del receptor x retinoide (rxr) en combinación con una hormona tiroidea para el tratamiento de esclerosis múltiple.
CL2025003126A1 (es) Anticuerpo biespecífico de cadena pesada anti-cd3 y anti-receptor de folato alfa (folr1).
MX2023012699A (es) Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3.
MX2022001022A (es) Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo.
EA202092967A1 (ru) Схемы приема иммуноконъюгата антитела против cd37
AR096601A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
MX2022005292A (es) Metodos de tratamiento con anticuerpos contra bcma y cd3.
MX2022001027A (es) Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.
MY209791A (en) Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
MX2021002531A (es) Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico.
MX2024012567A (es) Composiciones farmaceuticas de anticuerpos biespecificos anti-cd20/anti-cd3 y metodos de uso
CY1126559T1 (el) Παραδειγμα θεραπειας για θεραπεια συνδυασμου anti-cd19 αντισωματος και βενετοκλαξης
ZA202309150B (en) Antibody against nkp46 and application of antibody
MX2021004120A (es) Regimen de dosificacion para antagonistas de tfpi.
MX2023005131A (es) Dosis para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3 y conjugados anticuerpo farmaco anti-cd79b.